Display options
Cite
Rashidi M, Ziai SA, Moini Zanjani T, et al. Umbelliprenin is Potentially Toxic Against the HT29, CT26, MCF-7, 4T1, A172, and GL26 Cell Lines, Potentially Harmful Against Bone Marrow-Derived Stem Cells, and Non-Toxic Against Peripheral Blood Mononuclear Cells. Iran Red Crescent Med J. 2016;18(7):e35167doi: 10.5812/ircmj.35167.
Rashidi, M., Ziai, S. A., Moini Zanjani, T., Khalilnezhad, A., Jamshidi, H., & Amani, D. (2016). Umbelliprenin is Potentially Toxic Against the HT29, CT26, MCF-7, 4T1, A172, and GL26 Cell Lines, Potentially Harmful Against Bone Marrow-Derived Stem Cells, and Non-Toxic Against Peripheral Blood Mononuclear Cells. Iranian Red Crescent medical journal, 18(7), e35167. https://doi.org/10.5812/ircmj.35167
Rashidi, Mohsen, et al. "Umbelliprenin is Potentially Toxic Against the HT29, CT26, MCF-7, 4T1, A172, and GL26 Cell Lines, Potentially Harmful Against Bone Marrow-Derived Stem Cells, and Non-Toxic Against Peripheral Blood Mononuclear Cells." Iranian Red Crescent medical journal vol. 18,7 (2016): e35167. doi: https://doi.org/10.5812/ircmj.35167
Rashidi M, Ziai SA, Moini Zanjani T, Khalilnezhad A, Jamshidi H, Amani D. Umbelliprenin is Potentially Toxic Against the HT29, CT26, MCF-7, 4T1, A172, and GL26 Cell Lines, Potentially Harmful Against Bone Marrow-Derived Stem Cells, and Non-Toxic Against Peripheral Blood Mononuclear Cells. Iran Red Crescent Med J. 2016 May 14;18(7):e35167. doi: 10.5812/ircmj.35167. eCollection 2016 Jul. PMID: 27703798; PMCID: PMC5027671.
Copy Download .nbib Format: NLM
Share it on

Iran Red Crescent Med J. 2016 May 14;18(7):e35167. doi: 10.5812/ircmj.35167. eCollection 2016 Jul.

Umbelliprenin is Potentially Toxic Against the HT29, CT26, MCF-7, 4T1, A172, and GL26 Cell Lines, Potentially Harmful Against Bone Marrow-Derived Stem Cells, and Non-Toxic Against Peripheral Blood Mononuclear Cells.

Iranian Red Crescent medical journal

Mohsen Rashidi, Seyed Ali Ziai, Taraneh Moini Zanjani, Ahad Khalilnezhad, Hamidreza Jamshidi, Davar Amani

Affiliations

  1. Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
  2. Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.

PMID: 27703798 PMCID: PMC5027671 DOI: 10.5812/ircmj.35167

Abstract

BACKGROUND: Resistance to chemotherapy is a growing concern, thus natural anticancer agents are drawing the attention of many scientists and clinicians. One natural anticancer agent, umbelliprenin, is a coumarin produced by many species of

OBJECTIVES: We aimed to examine the inhibitory effect of umbelliprenin on human and mouse bone marrow-derived stem cells (BMDSCs), peripheral blood mononuclear cells (PBMCs), and different cancer cell lines.

MATERIALS AND METHODS: In this in vitro experimental study, the HT29, CT26, MCF-7, 4T1, A172, and GL26 cancer cells and human and mouse BMDSCs and PBMCs were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), incubated at 37°C for 24 hours in a 5% CO

RESULTS: Umbelliprenin inhibited the cancer cells in a concentration-dependent (P < 0.05) but not time-dependent manner (P > 0.05). The most sensitive and resistant cell lines at the 24-hour incubation time were 4T1 (IC

CONCLUSIONS: Our findings indicate that umbelliprenin exhibits concentration-dependent inhibitory effects on various cell types; it is potentially toxic against the HT29, CT26, MCF-7, 4T1, A172, and GL26 cell lines, potentially harmful against BMDSCs, and non-toxic against PBMCs. Therefore, if our results are approved in the future, umbelliprenin can be an appropriate candidate for developing treatments against different cancers.

Keywords: Inhibition; Natural Product; Neoplastic Cell; Umbelliprenin

Conflict of interest statement

Conflict of Interest:The authors declare that none has any conflict of interest.

References

  1. J Asian Nat Prod Res. 2014;16(8):884-9 - PubMed
  2. J Immunotoxicol. 2016;13(2):209-16 - PubMed
  3. Eur J Cancer Prev. 2009 Sep;18(5):412-5 - PubMed
  4. Chem Biol Interact. 2009 May 15;179(2-3):363-74 - PubMed
  5. Immunopharmacol Immunotoxicol. 2014 Feb;36(1):25-32 - PubMed
  6. Nat Protoc. 2009;4(1):102-6 - PubMed
  7. Biochem Pharmacol. 2009 Jun 15;77(12):1773-9 - PubMed
  8. Iran J Pharm Res. 2014 Fall;13(4):1387-92 - PubMed
  9. Iran J Pharm Res. 2013 Summer;12(3):371-6 - PubMed
  10. J Immunol Methods. 1983 Dec 16;65(1-2):55-63 - PubMed
  11. Metabolites. 2015 Sep 30;5(4):571-600 - PubMed
  12. Phytomedicine. 2006 Nov;13(9-10):712-7 - PubMed
  13. Pharm Biol. 2010 Feb;48(2):217-20 - PubMed
  14. Iran J Pharm Res. 2012 Spring;11(2):653-9 - PubMed
  15. Pharm Biol. 2010 Mar;48(3):242-6 - PubMed
  16. Daru. 2012 Oct 30;20(1):69 - PubMed
  17. Nat Rev Clin Oncol. 2015 Feb;12(2):105-13 - PubMed
  18. Ann Glob Health. 2014 Sep-Oct;80(5):346-57 - PubMed
  19. Phytomedicine. 2008 Jan;15(1-2):103-11 - PubMed
  20. Evid Based Complement Alternat Med. 2015;2015:767136 - PubMed

Publication Types